Fund+
Fund+ NV is a venture capital firm based in Leuven, Belgium, specializing in startup and early-stage investments within the life sciences sector. The firm focuses on companies involved in therapeutics, diagnostics, and medical devices, primarily targeting those in advanced development stages. Fund+ typically invests between EUR 3 million and EUR 8 million and aims to acquire a significant minority stake of 10% to 20% in its portfolio companies. Established in 2015, the firm is dedicated to creating sustainable shareholder value, fostering leadership in the life sciences industry, and generating positive societal impacts. Investment decisions are made by the Management Committee or the Board of Directors, based on the amount invested.
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses on creating therapies that enhance patient quality of life while minimizing side effects associated with existing treatments. EyeD Pharma collaborates with ophthalmologists to introduce new treatment options, as well as providing surgical products that support clinical practices. Through these efforts, EyeD Pharma aims to deliver therapeutic solutions that are currently lacking in the market, ultimately benefiting both healthcare providers and patients.
Novadip Biosciences SA is a biopharmaceutical company that develops process and distribution platform for tissue regeneration. It focuses on autologous cell therapies for critical size tissue reconstruction; allogeneic therapeutics for smaller and prevalent tissue defects; and miRNA/exosome-based therapeutics for systemic tissue and other diseases. The company was founded in 2013 and is based in Mont-Saint-Guibert, Belgium.
ExeVir Bio BV is a Belgium-based biotechnology company established in 2020, focused on developing single-domain antibody therapies to combat viral infections. The company utilizes a llama-derived antibody technology platform, specifically the VHH technology, to create robust antiviral treatments that offer broad protection against coronaviruses, including SARS-CoV-2. ExeVir's lead candidate, VHH72-FC, targets a conserved region on the virus's spike protein essential for cellular entry. This innovative approach not only aims to provide effective treatment and prevention strategies for viral infections but also enables rapid development of drug candidates in response to emerging health threats, ensuring stability and cost-effectiveness for global access. ExeVir Bio's therapies are designed to reduce viral load and inflammation, thereby supporting immune responses and protecting vulnerable populations, including healthcare workers and individuals with co-morbidities.
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses on creating therapies that enhance patient quality of life while minimizing side effects associated with existing treatments. EyeD Pharma collaborates with ophthalmologists to introduce new treatment options, as well as providing surgical products that support clinical practices. Through these efforts, EyeD Pharma aims to deliver therapeutic solutions that are currently lacking in the market, ultimately benefiting both healthcare providers and patients.
Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO® technology, Confo Therapeutics stabilizes inherently unstable functional conformations of GPCRs, providing a robust starting point for drug discovery. This approach reveals previously inaccessible structural features of these receptors, facilitating the identification of novel agonists that enhance therapeutic interventions.
Aelin Therapeutics NV is a Belgian biotherapeutics company founded in 2017, focused on developing antibiotics and therapeutics utilizing its innovative Pept-in technology. This technology leverages protein aggregation to achieve functional knockdown of target proteins, making it applicable against challenging conditions such as Methicillin-resistant Staphylococcus aureus (MRSA) and other undruggable targets in humans. Aelin Therapeutics was established as a collaboration between VIB and partner universities including KU Leuven, VUB, and UGent, building on the pioneering research of noted structural biologists. The company has compiled a robust preclinical proof of concept data package, demonstrating the diverse applications of its technology across various biological targets, including bacteria, cancer cells, fungi, viruses, and plant cells. Aelin Therapeutics differentiates itself through the unique mechanism of action of its Pept-in technology, which allows for the rational design of biotherapeutics that can target intracellular spaces often inaccessible to conventional small molecules or antibodies. The company is headquartered in Heverlee, Belgium.
OCTIMET oncology’s overall strategy is to advance the development of discovery stage molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.
Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):